Dynamic Technology Lab Private Ltd Makes New $575,000 Investment in Orthofix Medical Inc. $OFIX

Key Points

• Dynamic Technology Lab Private Ltd acquired 35,251 shares of Orthofix Medical Inc., valued at approximately $575,000, increasing its stake in the company to about 0.09% as of the latest SEC filing.
• Several research firms have recently upgraded their ratings for Orthofix Medical, with Barrington Research issuing a "strong-buy" rating and setting a price target of $16.00, while analysts have a consensus rating of "Buy" and an average target price of $21.50.
• Orthofix Medical reported a loss of ($0.36) EPS for the recent quarter, significantly missing analysts' estimates, while revenue exceeded expectations at $203.12 million.

Dynamic Technology Lab Private Ltd acquired a new position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 35,251 shares of the medical device company's stock, valued at approximately $575,000. Dynamic Technology Lab Private Ltd owned approximately 0.09% of Orthofix Medical at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Northern Trust Corp boosted its holdings in shares of Orthofix Medical by 8.8% during the 4th quarter. Northern Trust Corp now owns 368,088 shares of the medical device company's stock worth $6,427,000 after purchasing an additional 29,768 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Orthofix Medical by 5.9% during the 4th quarter. BNP Paribas Financial Markets now owns 36,798 shares of the medical device company's stock worth $642,000 after purchasing an additional 2,040 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Orthofix Medical by 14.0% during the 4th quarter. Bank of America Corp DE now owns 48,608 shares of the medical device company's stock worth $849,000 after purchasing an additional 5,966 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in shares of Orthofix Medical by 139.1% during the 4th quarter. Balyasny Asset Management L.P. now owns 38,623 shares of the medical device company's stock worth $674,000 after purchasing an additional 22,471 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of Orthofix Medical by 21.6% during the 4th quarter. Deutsche Bank AG now owns 86,486 shares of the medical device company's stock worth $1,510,000 after purchasing an additional 15,386 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Orthofix Medical Trading Up 0.6%

OFIX traded up $0.09 during trading hours on Tuesday, reaching $14.84. The company's stock had a trading volume of 260,432 shares, compared to its average volume of 419,096. Orthofix Medical Inc. has a fifty-two week low of $10.24 and a fifty-two week high of $20.73. The stock has a market cap of $586.03 million, a PE ratio of -4.68 and a beta of 0.86. The business's 50-day moving average is $13.05 and its 200-day moving average is $13.20. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The business had revenue of $203.12 million during the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,728 shares of the company's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the transaction, the insider directly owned 46,322 shares in the company, valued at $486,844.22. This represents a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on OFIX. Barrington Research upgraded Orthofix Medical to a "strong-buy" rating and set a $16.00 target price on the stock in a report on Monday, June 23rd. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Finally, Wall Street Zen upgraded Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $21.50.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.